Overview
EOLS market data
Price History
EOLS price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.80 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.37 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -14.4% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.86 – $8.43 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $540.6M · P/B 126.60 · P/S 1.79.
Company News
Evolus Q2 EPS $(0.12), Sales $84.084M Beat $81.603M EstimateBenzinga · Aug 5, 2026, 8:28 PM
Evolus Raises FY2026 Sales Guidance from $327.000M-$337.000M to $330.000M-$337.000M vs $330.445M EstBenzinga · Aug 5, 2026, 8:09 PM
8-K filing — Evolus, Inc. (EOLS)SEC EDGAR · Aug 4, 2026, 12:46 PM
Evolus Announces Expanded Symatese Agreement For Exclusive Estyme HA Gel Rights In Canada, Australia, New Zealand; Terms Not DisclosedBenzinga · Aug 4, 2026, 12:35 PM
Evolus Enters Into Exclusive Licensing And Distribution Agreement With IBSA To Develop And Commercialize Profhilo In USBenzinga · Jul 8, 2026, 1:10 PM
Evolus Files Prospectus To Offer Up To $250M Of SecuritiesBenzinga · Jun 5, 2026, 8:55 PM
AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache SocietyGlobenewswire Inc · Jun 4, 2026, 11:15 AM
Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing ItBenzinga · May 22, 2026, 3:15 PM